Conditions: Solid Cancers
Keywords: Advanced solid cancers HER2 EGFR
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 3
Healthy volunteers: no

Brief summary:
This is a multicenter, open label extension study. Subjects who have completed treatment in the parent study of pertuzumab, either alone or with a combination agent, and who received at least one dose of pertuzumab in the parent study are eligible for inclusion in this trial if they are continuing to receive clinical benefit.

Detailed description:

Arms:
arm 1: Participants received the same dose of pertuzumab that they received in their parent Phase II trial, either 420 mg or 1050 mg, intravenously on Day 1 of every 3 week cycle until disease progression.

Interventions: intervention 1: Pertuzumab
Intervention descriptions: intervention 1: Pertuzumab was supplied as a single-use liquid formulation.

Protocol document: